Register      Login
Microbiology Australia Microbiology Australia Society
Microbiology Australia, bringing Microbiologists together
RESEARCH ARTICLE

The future of mucosal HIV vaccines

Jeanette Reece and Stephen Kent

Microbiology Australia 32(3) 118 - 119
Published: 01 September 2011

Abstract

Approximately 33 million people live with the human immunodeficiency virus (HIV) and 2.6 million new infections are acquired each yea1. The development of an effective HIV vaccine that induces robust mucosal immunity represents a major global public health challenge. Large human efficacy trials of simple antibody-based and cytotoxic T cell-based vaccines have failed to provide any protection. The recent RV144 HIV vaccine efficacy trial in Thailand using a prime-boost combination of vaccines, however, showed modest efficacy (31%, p=0.04 on the primary analysis). Although the efficacy was marginal, the study has provided considerable hope that a vaccine to prevent infection by HIV may be feasible.

https://doi.org/10.1071/MA11118

© CSIRO 2011

Committee on Publication Ethics

PDF (807 KB) Export Citation

Share

Share on Facebook Share on Twitter Share on LinkedIn Share via Email